Health Affairs January 18, 2026
Sayeh Nikpay, Mikayla Reinke, and Elizabeth Watts

Abstract

The Medicaid Drug Rebate Program and the 340B Drug Pricing Program are generally understood as separate efforts to promote drug affordability—one by directly subsidizing low-income patients through insurance coverage (Medicaid) and the other by indirectly subsidizing safety-net clinics and hospitals (340B). Yet they interact in ways that can unintentionally raise costs for Medicaid....

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Health System / Hospital, Insurance, Medicaid, Pharma, Pharma / Biotech, Provider
Medicaid and Upcoming State Budget Debates
The Future of Medi-Cal: Bold Ideas for the Next Decade
Medicaid: What to Watch in 2026
An Optimist’s Take on What's Next for Health Tech in Medicaid
Advancing Medicaid Primary Care Population-Based Payment Models: Four Lessons for States

Share Article